502 related articles for article (PubMed ID: 23229955)
1. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
2. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
4. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
5. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
[TBL] [Abstract][Full Text] [Related]
6. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
7. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
[TBL] [Abstract][Full Text] [Related]
8. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
9. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
10. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
12. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent.
Zou W; Luo C; Zhang Z; Liu J; Gu J; Pei Z; Qian C; Liu X
Oncogene; 2004 Jan; 23(2):457-64. PubMed ID: 14724574
[TBL] [Abstract][Full Text] [Related]
13. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
14. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
[TBL] [Abstract][Full Text] [Related]
15. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.
Majem M; Cascallo M; Bayo-Puxan N; Mesia R; Germa JR; Alemany R
Cancer Gene Ther; 2006 Jul; 13(7):696-705. PubMed ID: 16498429
[TBL] [Abstract][Full Text] [Related]
16. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma.
Zhang W; Cai R; Luo J; Wang Y; Cui Q; Wei X; Zhang H; Qian C
Cancer Biol Ther; 2007 Nov; 6(11):1726-32. PubMed ID: 18281783
[TBL] [Abstract][Full Text] [Related]
17. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.
Kim E; Kim JH; Shin HY; Lee H; Yang JM; Kim J; Sohn JH; Kim H; Yun CO
Hum Gene Ther; 2003 Oct; 14(15):1415-28. PubMed ID: 14577922
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
[TBL] [Abstract][Full Text] [Related]
19. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
[TBL] [Abstract][Full Text] [Related]
20. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
